Global Opioid Induced Constipation Drugs Market, By Active Ingredients (Naloxegol, Lubiprostone, Methylnaltrexone Bromide, Docusate Sodium, and Others), Treatment (Over The Counter Medicines, Prescription, and Natural Remedies), Mode of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031.
Opioid Induced Constipation Drugs Market Analysis and Size
According to a report published by the National Center for Biotechnology Information, chronic pain is characterized by persistent discomfort lasting for three months or longer, affecting approximately 10–15% of the population. Among individuals experiencing chronic non-cancer pain, the prevalence of opioid-induced constipation ranges from 41% to 81%.
The global opioid induced constipation drugs market size was valued at USD 2.69 billion in 2023 and is projected to reach USD 4.52 billion by 2031, with a CAGR of 6.7% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016 - 2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Active Ingredients (Naloxegol, Lubiprostone, Methylnaltrexone Bromide, Docusate Sodium, and Others), Treatment (Over The Counter Medicines, Prescription, and Natural Remedies), Mode of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan NV (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (US.) GSK Plc. (U.K.), Bayer AG (Germany), Aurobindo Pharma (India), SLA Pharma AG (U.K.), Salix Pharmaceuticals (U.S.), Takeda Pharmaceutical Company Limited (Japan), Abbott (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Daewoong Pharmaceutical Company (South Korea), and Cosmo Pharmaceuticals (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Opioid-induced constipation drugs are medications specifically designed to alleviate constipation caused by the use of opioid pain relievers. These drugs work by targeting the receptors in the gastrointestinal tract affected by opioids, helping to restore normal bowel function and relieve constipation without interfering with the pain-relieving effects of opioids. They are an essential component of pain management strategies for individuals who experience constipation as a side effect of opioid therapy.
Opioid Induced Constipation Drugs Market Dynamics
Drivers
- Increasing Prevalence of Opioid Use
The rise in opioid prescriptions for pain relief has significantly increased the incidence of opioid-induced constipation (OIC) worldwide. Opioids are commonly prescribed for chronic pain conditions, such as cancer-related pain or severe injuries, contributing to the growing number of individuals experiencing OIC. As a result, there is a greater need for effective drugs for OIC to manage this common side effect of opioid therapy and improve patient quality of life, which is a major factor driving the market growth.
- Accelerated Drug Approval Initiatives
Regulatory agencies have implemented programs to expedite the approval process for new opioid-induced constipation (OIC) drugs. These initiatives aim to address the urgent need for effective treatments by reducing the time and resources required for drug development and approval. Making the regulatory process simpler helps pharmaceutical companies introduce new OIC drugs to the market faster, giving patients access to innovative treatments sooner. This accelerated approval pathway has significantly contributed to the expansion of the OIC drug market.
- Advancements in Drug Delivery Technology
Continuous innovations in drug delivery technology are driving the development of more effective and patient-friendly opioid-induced constipation (OIC) drugs. Novel delivery systems, such as controlled-release formulations and targeted drug delivery mechanisms, are designed to optimize OIC drugs' therapeutic effects while minimizing adverse effects like constipation. These advancements improve patient compliance and satisfaction and enhance the overall efficacy and safety profiles of OIC medications. Consequently, the evolution of drug delivery technology acts as a significant driver for the market's growth, fostering innovation and market expansion.
Opportunities
- Expanding Geriatric Population
As the global population ages, there is a notable increase in the number of elderly individuals who require opioid therapy for chronic pain management. This demographic is more susceptible to opioid-induced constipation (OIC) due to age-related changes in gastrointestinal function. Addressing the specific requirements of older population such as dosage adjustments and personalized treatment plans can create new opportunities for market growth.
- Personalized OIC Treatments
Tailored OIC therapies can address specific patient needs, potentially reducing side effects and improving treatment efficacy. This patient-centered approach aligns with the broader trend toward personalized healthcare, offering more targeted and efficient solutions for managing OIC. Personalized OIC treatments can optimize treatment plans, ensuring patients receive the most effective therapies for their specific condition. This can lead to improved symptom management and overall treatment efficacy, which will help new opportunities arise in the market.
Restraints/Challenges
- Safety Concerns Impacting OIC Drugs
The safety profile of opioid medications, including the potential for addiction and overdose, significantly influences the adoption and use of opioid-induced constipation (OIC) drugs. Healthcare providers and patients are often wary of using opioids due to these safety concerns, which can lead to hesitancy in prescribing and reluctance in seeking treatment and create challenges for the market.
- Stigma and Misconceptions
There is a stigma associated with opioid use, which can lead to misconceptions about the need for OIC drugs and reluctance among patients to seek treatment. This stigma can also impact healthcare provider attitudes and prescribing practices, affecting the uptake of OIC drugs and hindering market growth.
This opioid induced constipation drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the opioid induced constipation drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2022, Bausch Health Companies Inc. and its gastroenterology division, Salix Pharmaceuticals, announced research findings indicating that patients who received FDA-approved prescription medications for opioid-induced constipation (OIC-Rx), such as RELISTOR subcutaneous injection (SC) (methylnaltrexone bromide), in the emergency department (ED) were less likely to require hospitalization. Moreover, those who were hospitalized had shorter stays compared to patients who did not receive OIC-Rx in the ED. These results underscore the potential of RELISTOR SC to offer relief for individuals with OIC.
- In January 2022, BioGaia Pharma reported the enrollment of the first patient in a Phase II clinical study evaluating BGP345A for the treatment of opioid-induced constipation (OIC-1).
- In February 2021, Cosmo Pharmaceuticals revealed a partnership with RedHill Biopharma Ltd. for the production of Movantik, intended for the treatment of opioid-induced constipation (OIC) in adult patients.
Opioid Induced Constipation Drugs Market Scope
The opioid induced constipation drugs market is segmented on the basis of active ingredient, treatment, route of administration, distribution channel, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Active Ingredients
- Naloxegol
- Lubiprostone
- Methylnaltrexone Bromide
- Docusate Sodium
- Others
Treatment
- Over The Counter Medicines
- Prescription
- Natural Remedies
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Opioid Induced Constipation Drugs Market Regional Analysis/Insights
The opioid induced constipation drugs market is analyzed and market size insights and trends are provided by country, active ingredient, treatment, route of administration, distribution channel, and end-user as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate the market due to the presence of major product manufacturers, which contributes to a robust market presence and availability of OIC drugs. The region is witnessing a significant increase in research and development efforts aimed at developing innovative treatments for OIC, further driving market growth. Substantial healthcare expenditure for addressing gastrointestinal disorders, including OIC, underscores the importance and demand for effective OIC drugs in the region.
Asia-Pacific is expected to witness significant growth due to the increase in new research and developments concerning opioid-induced constipation drugs. The region benefits from advanced healthcare infrastructure availability and earlier drug approvals for opioid-induced constipation drugs, courtesy of the accelerated drug approval initiative by the U.S. FDA, which is likely to propel market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The opioid induced constipation drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for opioid induced constipation drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the opioid induced constipation drugs market. The data is available for historic period 2011-2021.
Competitive Landscape and Opioid Induced Constipation Drugs Market Share Analysis
The opioid induced constipation drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Aurobindo Pharma (India)
- S.L.A. Pharma AG (U.K.)
- Salix Pharmaceuticals (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Abbott(U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Daewoong Pharmaceutical Company (South Korea)
- Cosmo Pharmaceuticals (Ireland)
SKU-